Fusion Pharmaceuticals and Niowave Announce Actinium-225 Collaboration and Supply Agreement

/PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radio pharmaceuticals as...

Related Keywords

Boston ,Massachusetts ,United States ,Denise Boucke ,John Valliant ,Terry Grimm ,Amanda Cray ,Fusion Pharmaceuticals Inc ,Mcmaster University ,Niowave Inc ,National Nuclear Security Administration ,Human Resources Administration ,Nasdaq ,Us Department Of Energy ,Astrazeneca ,Fusion Pharmaceuticals ,Prnewswire Fusion Pharmaceuticals Inc ,Investor Relations Corporate Communications ,Fusion Chief Executive Officer John Valliant ,Niowave Chief Executive ,Senior Scientist Terry Grimm ,Repair Inhibitors ,Ontario Based Mcmaster University ,Good Manufacturing Practice ,Cooperative Agreement ,Private Securities Litigation Reform Act ,Investor Relations ,Human Resources ,